MTOR and non-small cell lung carcinoma: Because rapamycin has broad anti-proliferative activity across a series of NSCLC cell lines, we hypothesized that combining rapamycin with pemetrexed might enhance mTOR inhibition, suppress TS expression, and synergistically decrease proliferation of NSCLC cells.